Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Uproleselan Plus Chemotherapy Fails to Improve EFS in Older Patients With AML

October 29th 2024

Uproleselan plus 7+3 chemotherapy failed to improve EFS vs chemotherapy alone in older patients with newly diagnosed AML fit for intensive chemotherapy.

BGB-16673 Shows Early Activity, Tolerability in Heavily Pretreated Waldenström Macroglobulinemia

October 29th 2024

BGB-16673 had acceptable tolerability and showcased early antitumor activity in patients with relapsed/refractory Waldenström macroglobulinemia.

FDA Expands Approval of Methotrexate to Include Pediatric Acute Lymphoblastic Leukemia

October 29th 2024

The FDA has expanded the approval of methotrexate to include use in pediatric patients with acute lymphoblastic leukemia.

Rezatapopt Monotherapy Remains Under Study Following Discontinuation of Combination Cohort in TP53+ Solid Tumors

October 28th 2024

PMV Pharmaceuticals has provided an update on the PYNNACLE trial investigating rezatapopt in TP53 Y220C–mutated solid tumors.

Bispecific Antibodies, Novel Combinations Highlight Continued Treatment Evolution in Follicular Lymphoma

October 26th 2024

David C. Fisher, MD, discusses the evolving therapeutic landscape in follicular lymphoma.

Nivolumab Plus AVD Prolongs PFS vs Brentuximab Vedotin Plus AVD in Advanced-Stage Hodgkin Lymphoma

October 25th 2024

Nivolumab plus AVD prolonged median PFS vs brentuximab vedotin plus AVD in patients with stage III or IV advanced-stage classic Hodgkin lymphoma.

FDA Grants Fast Track Designation to HC-7366 in Relapsed/Refractory AML

October 25th 2024

HC-7366 has received FDA fast track designation for the treatment of adult patients with relapsed/refractory acute myeloid leukemia.

Dr Awan on the Evolving Role of Bispecific Antibodies Treatment in DLBCL

October 25th 2024

Farrukh Awan, MD, discuses the evolving role of bispecific antibodies in the treatment paradigm of diffuse large B-cell lymphoma.

Dr Battiwalla on Limitations to CAR T-Cell Therapy Access in Hematologic Malignancies

October 24th 2024

Minoo Battiwalla, MD, MS, discusses both the benefits and the limitations of treatment with CAR T-cell therapy across hematologic malignancies.

The Role of Genetic Profiling in Secondary AML

October 24th 2024

James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.

Goals in the Treatment of Secondary AML

October 24th 2024

James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.

Factors When Weighing Intensive Chemotherapy vs Other Regimens in Secondary AML

October 24th 2024

James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.

Dose Intensity and Sequencing of Intensive Chemotherapy in Secondary AML

October 24th 2024

James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.

Long-Term Data for CPX-351 in Secondary AML

October 24th 2024

James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss long-term data for CPX-351 in acute myeloid leukemia.

Defining Intensive Chemotherapy Fitness in AML

October 24th 2024

James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss factors to help determine intensive chemotherapy fitness in acute myeloid leukemia.

The Diagnosis and Prevalence of Secondary AML

October 24th 2024

James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss the diagnosis and prevalence of secondary acute myeloid leukemia.

NX-5948 Generates Responses in R/R Waldenström Macroglobulinemia

October 22nd 2024

Treatment with the BTK degrader NX-5948 led to responses in patients with relapsed/refractory Waldenström macroglobulinemia.

Dr Battiwalla on the Potential Roles of FLT3-ITD and Menin Inhibitors in AML Management

October 21st 2024

Minoo Battiwalla, MD, MS, discusses the potential of FLT3-ITD and menin inhibitors to broaden the acute myeloid leukemia treatment paradigm.

New Global Hematology Journal Strives to Feature Innovative and Adaptable Research

October 21st 2024

Jorge Cortes, MD, inaugural editor-in-chief of Blood Global Hematology, details what type of research the new journal will highlight and its importance.

Asciminib Yields Promising Efficacy vs SOC Agents in CML

October 17th 2024

Jorge Cortes, MD, details how asciminib could affect care for patients with CML, diving into key takeaways from the ASC4FIRST trial.